Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Aura Biosciences, Inc. AURA

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$-106.2M
$-85.2M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 6-year series below
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
ROE
FY2025 · ROE -73.5%
-20%-40%-60%
202020222025
Three returns, three denominators.

Each USD of equity lost 74 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -85.2
-30M-60M
202020222025

Total assetsUSD 169.4M
EquityUSD 136.9M
CashUSD 59.5M
Current ratio8.15×

Equity funds 81% of total assets.

The 6-year record

6 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
AURA, 6-year financial record
Metric 202520242023202220212020
Revenue $B◌◌◌◌◌◌
Operating income $B−0.1−0.1−0.1−0.1−0.0−0.0
EBITDA $B−0.1−0.1−0.1−0.1−0.0−0.0
Income tax $B0.00.00.00.00.00.0
Net income $B−0.1−0.1−0.1−0.1−0.0−0.0
Free cash flow $B−0.1−0.1−0.1−0.1−0.0−0.0
EPS, diluted $−1.76−1.75−1.93−1.96−8.95−82.06
Dividend / sh $◌◌◌◌◌◌
Payout % — not applicable: no dividend——————
ROE %−73.5−46.0−36.3−33.8——
Shares out B0.060.050.050.040.030.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 2 failures in 24 reconciliationsAUDITED

Reconciled in 4 of the 6 fiscal years we could check. 26 checks were skipped: the balance sheet is not tagged before 2020. 13 checks were skipped: EPS is not tagged before 2020.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency2 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2020

Share this section

Download image